10.1371/journal.pone.0150602.g008
Martilias S. Farrell
Martilias
S. Farrell
John D. McCorvy
John D.
McCorvy
Xi-Ping Huang
Xi-Ping
Huang
Daniel J. Urban
Daniel
J. Urban
Kate L. White
Kate
L. White
Patrick M. Giguere
Patrick
M. Giguere
Allison K. Doak
Allison K.
Doak
Alison I. Bernstein
Alison
I. Bernstein
Kristen A. Stout
Kristen A.
Stout
Su Mi Park
Su
Mi Park
Ramona M. Rodriguiz
Ramona M.
Rodriguiz
Bradley W. Gray
Bradley
W. Gray
William S. Hyatt
William
S. Hyatt
Andrew P. Norwood
Andrew
P. Norwood
Kevin A. Webster
Kevin
A. Webster
Brenda M. Gannon
Brenda
M. Gannon
Gary W. Miller
Gary W.
Miller
Joseph H. Porter
Joseph
H. Porter
Brian K. Shoichet
Brian K.
Shoichet
William E. Fantegrossi
William E.
Fantegrossi
William C. Wetsel
William C.
Wetsel
Bryan L. Roth
Bryan L.
Roth
Locomotor studies of nuciferine.
Public Library of Science
2016
D 4 receptors
drug discrimination paradigms.ResultsNuciferine shares
2A
2B
2C
PCP
HT
discriminative stimulus effects
antipsychotic drug action
nuciferine
agonist
clozapine discriminative stimulus
1A
Nelumbo nucifera
Alkaloid Nuciferine RationaleThe
similarity ensemble approach
profile
Psychoactive Drug Screening Program
2016-03-10 09:18:08
Figure
https://plos.figshare.com/articles/figure/Locomotor_studies_of_nuciferine_/3108409
<p>(a) Nuciferine suppresses the PCP-induced hyperlocomotor response. Data are presented as total distance travelled in 5-minute bins (left) and as cumulative distance travelled between minute 45 and minute 60 (right). N = 18 mice; ^p<0.05, compared to PCP group. (b) Nuciferine (3.0 mg/kg, 15 minute pretreatment) enhances the hyperlocomotor effect of amphetamine (3.0 mg/kg) administration. N = 14 mice; * < 0.001 compared to Amphetamine group. Data are presented as above.</p>